# Entia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/entia

- Industry: Medical Devices & Equipment
- Headquarters: London, UK
- Website: www.entia.co
- Total disclosed funding: $39M
- Latest round: Series A (Jul 26, 2023)
- Investors on record: 4

## About

Entia Ltd., based in the UK, specializes in at-home blood monitoring solutions, empowering patients to perform their own blood tests. This innovative approach enhances proactive health management for users, ultimately improving healthcare delivery.Founded in 2014 and headquartered in London, UK, Entia Ltd. offers advanced blood monitoring solutions for home use. The company has successfully completed four deals, with the most recent on July 26, 2023, involving a Series A funding round that raised GBP 16 million, co-led by BGF and Parkwalk Advisors, among others. Alberto García and Toby Basey-Fisher serve as the CEO.Entia's primary offering is the Liberty at-home blood monitoring solution, the first of its kind designed for patients to perform their own blood tests from home. This innovative system enables users to conduct tests related to blood counts, liver function, kidney function, electrolytes, and immune markers, thereby streamlining the process of routine health assessments and promoting proactive care. The simplicity of the tests allows patients to gain insights into their health status, ultimately facilitating personalized and preventative care pathways within communities. Liberty integrates seamlessly with existing clinical practices and patient support programs, and it is interoperable with various digital health solutions, enhancing its utility. The product is designed for a wide range of end users, including patients undergoing cancer treatment and those managing chronic health conditions, and is marketed primarily in Great Britain and select European countries.Entia's revenue model centers around the sale of its flagship product, the Liberty blood monitoring system, directly to consumers and healthcare providers. Transactions typically occur through a combination of direct-to-consumer sales and partnerships with healthcare institutions that incorporate the testing solutions into their patient care programs. The company establishes pricing plans which are structured to cater to both individual consumers and healthcare providers, facilitating accessibility for a diverse client base. By focusing on a subscription model for ongoing support and testing supplies, along with potential partnerships with pharmaceutical companies for integrated healthcare solutions, Entia positions itself for sustainable revenue generation. The unique value proposition of the Liberty system, combined with its application in personalized healthcare, underscores the firm's strategy to capture market share in the evolving landscape of at-home diagnostics.In July 2023, Entia Ltd. raised GBP 16 million in Series A funding to support the launch of its product in the UK and to pursue regulatory approval in the US. The company is focused on expanding into new geographic regions, with specific plans to penetrate the US market by facilitating access to its innovative blood monitoring solutions. The recent funding will be instrumental in achieving these strategic objectives.

## Funding rounds

- Series A, Jul 26, 2023, $21M — Sussex Place Ventures, BGF Investment Management, Parkwalk Advisors, Innovate UK
- Series A, Mar 24, 2021, $12M — Sussex Place Ventures, BGF Investment Management, Parkwalk Advisors
- Series A, Mar 8, 2019, $5.7M — Parkwalk Advisors
- Seed, May 19, 2016, $1.4M — Sussex Place Ventures

## Investors

- Sussex Place Ventures (https://capitalatlas.ai/funds/sussex-place-ventures) — Seed, Series A
- Parkwalk Advisors (https://capitalatlas.ai/funds/parkwalk-advisors) — Series A
- BGF Investment Management (https://capitalatlas.ai/funds/bgf-investment-management) — Series A
- Innovate UK — Series A